Literature DB >> 17431670

Expression and prognostic significance of Tetranectin in invasive and non-invasive bladder cancer.

A Brunner1, C Ensinger, M Christiansen, S Heiss, I Verdorfer, G Mikuz, A Tzankov.   

Abstract

Tetranectin (TN) is a plasminogen kringle-4 binding protein that can be detected in the plasma and the extracellular matrix. In malignancies, TN is thought to enhance proteolytic processes enabling tumor cells to invade and metastasize. So far, TN expression has not been described in transitional cell bladder cancer (TCC), and there is no information on the prognostic significance of its in situ expression. TN expression was studied in 99 TCC patients diagnosed between 1994 and 1997. Immunohistochemistry was performed on a tissue microarray using a monoclonal antibody against TN (clone 11F1). Within the mean follow-up period of 60 months, pTa and pT2-4 TCC patients with stainable TN in the tumor stroma had a significant shorter recurrence-free survival and higher risk of recurrence compared to those without stainable TN (p = 0.0002 for both). TN expression in the tumor cells did not influence recurrence-free survival. In conclusion, TN is expressed in a subgroup of bladder cancer patients with a higher risk of recurrence who may take benefit from a closer follow-up.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17431670     DOI: 10.1007/s00428-007-0409-4

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  27 in total

Review 1.  The distribution of fibronectin, laminin and tetranectin in human breast cancer with special attention to the extracellular matrix.

Authors:  L Christensen
Journal:  APMIS Suppl       Date:  1992

2.  Tetranectin immunoreactivity in normal human tissues. An immunohistochemical study of exocrine epithelia and mesenchyme.

Authors:  L Christensen; I Clemmensen
Journal:  Histochemistry       Date:  1989

3.  The heparin-binding site in tetranectin is located in the N-terminal region and binding does not involve the carbohydrate recognition domain.

Authors:  R H Lorentsen; J H Graversen; N R Caterer; H C Thogersen; M Etzerodt
Journal:  Biochem J       Date:  2000-04-01       Impact factor: 3.857

4.  Tetranectin expression in gastric adenocarcinomas.

Authors:  D L Arvanitis; E F Kamper; L Kopeikina; A Stavridou; M N Sgantzos; V Kallioras; E Athanasiou; P Kanavaros
Journal:  Histol Histopathol       Date:  2002-04       Impact factor: 2.303

5.  Immunohistochemical localization of a novel, human plasma protein, tetranectin, in human endocrine tissues.

Authors:  L Christensen; N Johansen; B A Jensen; I Clemmensen
Journal:  Histochemistry       Date:  1987

6.  Differences in tetranectin immunoreactivity between benign and malignant breast tissue.

Authors:  L Christensen; I Clemmensen
Journal:  Histochemistry       Date:  1991

7.  Tetranectin binds hepatocyte growth factor and tissue-type plasminogen activator.

Authors:  Uffe B Westergaard; Mikkel H Andersen; Christian W Heegaard; Sergey N Fedosov; Torben E Petersen
Journal:  Eur J Biochem       Date:  2003-04

8.  Tetranectin: a novel secretory protein from human monocytes.

Authors:  H Nielsen; I Clemmensen; A Kharazmi
Journal:  Scand J Immunol       Date:  1993-01       Impact factor: 3.487

9.  Plasma tetranectin and ovarian neoplasms.

Authors:  C K Høgdall; E V Høgdall; U Hørding; S Daugaard; I Clemmensen; B Nørgaard-Pedersen; K Toftager-Larsen
Journal:  Gynecol Oncol       Date:  1991-11       Impact factor: 5.482

10.  Tetranectin Binds to the Kringle 1-4 Form of Angiostatin and Modifies Its Functional Activity.

Authors:  Tirsit Mogues; Michael Etzerodt; Crystal Hall; Georg Engelich; Jonas H. Graversen; Kevan L. Hartshorn
Journal:  J Biomed Biotechnol       Date:  2004
View more
  8 in total

1.  Cancer-associated fibroblasts promote colorectal cancer progression by secreting CLEC3B.

Authors:  Hui-Fang Zhu; Xu-Hui Zhang; Chuan-Sha Gu; Yan Zhong; Ting Long; Yi-Dan Ma; Zhi-Yan Hu; Zu-Guo Li; Xiao-Yan Wang
Journal:  Cancer Biol Ther       Date:  2019-03-20       Impact factor: 4.742

2.  The role of structural extracellular matrix proteins in urothelial bladder cancer (review).

Authors:  Andrea Brunner; Alexandar Tzankov
Journal:  Biomark Insights       Date:  2007-11-05

3.  Identification of tetranectin as a potential biomarker for metastatic oral cancer.

Authors:  Martha E Arellano-Garcia; Roger Li; Xiaojun Liu; Yongming Xie; Xiaofei Yan; Joseph A Loo; Shen Hu
Journal:  Int J Mol Sci       Date:  2010-09-02       Impact factor: 5.923

4.  Tetranectin as a Potential Biomarker for Stable Coronary Artery Disease.

Authors:  Yanjia Chen; Hui Han; Xiaoxiang Yan; Fenghua Ding; Xiuxiu Su; Haibo Wang; Qiujing Chen; Lin Lu; Ruiyan Zhang; Wei Jin
Journal:  Sci Rep       Date:  2015-12-01       Impact factor: 4.379

5.  iTRAQ-based Comparative Serum Proteomic Analysis of Prostate Cancer Patients with or without Bone Metastasis.

Authors:  Bo Yan; Binshen Chen; Shaoju Min; Yubo Gao; Yiming Zhang; Peng Xu; Chaoming Li; Jiasheng Chen; Guangheng Luo; Chunxiao Liu
Journal:  J Cancer       Date:  2019-07-10       Impact factor: 4.207

6.  CLEC3B as a Potential Prognostic Biomarker in Hepatocellular Carcinoma.

Authors:  Xing-Wei Xie; Shan-Shan Jiang; Xiang Li
Journal:  Front Mol Biosci       Date:  2021-01-20

7.  High Intratumoral Expression of Tetranectin Associates with Poor Prognosis of Patients with Gastric Cancer after Gastrectomy.

Authors:  Hao Chen; Haojie Li; Junjie Zhao; Peike Peng; Miaomiao Shao; Hao Wu; Xuefei Wang; Ling Chen; Qi Zhang; Yuanyuan Ruan; Fenglin Liu; Yihong Sun
Journal:  J Cancer       Date:  2017-10-09       Impact factor: 4.207

8.  The relationship between the expression of TN and the efficiency of posterior spinal V osteotomy in patients with traumatic kyphosis.

Authors:  Guohua Jiang; Yinshun Zhang; Xianjie Sun
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.